Cellares, an Integrated Development and Manufacturing Organization (IDMO), has joined forces with the Stanford Center for Definitive and Curative Medicine (CDCM) and Stanford Innovative Medicines Accelerator (IMA) to automate manufacturing and release testing for gene-edited hematopoietic stem cell (HSC) therapies, expanding the application of Cellares’ automation platforms beyond T cell therapies into a new cell modality.

Gene-edited HSCs are being developed as durable, potentially one-time treatments that rebuild the blood and immune system with corrected cells for patients with HIV and rare inherited diseases. Many of these conditions currently lack effective treatment options, highlighting the need for scalable, reliable manufacturing approaches that can support patient access as programs advance.

Under the collaboration, Cellares will establish a standardized platform manufacturing process on the Cell Shuttle and platform release assays on the Cell Q, designed to apply across multiple indications. Automation efforts are already underway with the HARBOR KNOCK (safe harbor knock-in) gene-editing approach.

The effort is supported by the Stanford Innovative Medicines Accelerator (IMA) and Stanford Medicine Center for Definitive and Curative Medicine (CDCM). The collaboration aims to reduce hands-on variability and create a scalable foundation to help move academic innovation toward clinical development.

“Gene-edited hematopoietic stem cells have the potential to address the root cause of disease for patients who today have limited or no treatment options,” said Fabian Gerlinghaus, Co-founder and CEO of Cellares. “With Stanford Medicine, we’re building a manufacturing and analytical foundation that can be applied across many rare disease programs to improve patient access.”